Agios Pharmaceuticals Company Profile (NASDAQ:AGIO)

Analyst Ratings

Consensus Ratings for Agios Pharmaceuticals (NASDAQ:AGIO) (?)
Ratings Breakdown: 5 Hold Rating(s), 5 Buy Rating(s)
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $63.88 (45.63% upside)

Analysts' Ratings History for Agios Pharmaceuticals (NASDAQ:AGIO)
Show:
DateFirmActionRatingPrice TargetActions
7/12/2016Credit Suisse Group AGReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/13/2016Goldman Sachs Group Inc.Reiterated RatingHold$46.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/13/2016Janney Montgomery ScottReiterated RatingNeutral$52.00 -> $47.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/13/2016JPMorgan Chase & Co.UpgradeNeutral -> Overweight$50.00 -> $62.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/13/2016Canaccord GenuityUpgradeHold -> Buy$50.00 -> $90.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/24/2016Cowen and CompanyReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/19/2016Leerink SwannReiterated RatingMarket Perform$56.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/18/2016SunTrust Banks Inc.Boost Price TargetBuy$57.00 -> $65.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/9/2015Roth CapitalLower Price TargetNeutral$114.00 -> $75.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/9/2015Oppenheimer Holdings Inc.Reiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/22/2015Northland SecuritiesInitiated CoverageOutperform$132.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
7/2/2015DesjardinsUpgradeHold -> BuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/2/2015Citigroup Inc.Initiated CoverageNeutral$132.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/8/2015MLV & Co.Initiated CoverageBuy$130.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/29/2014 forward)

Earnings

Earnings History for Agios Pharmaceuticals (NASDAQ:AGIO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/4/2016ListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/5/2016Q116($0.79)($0.61)$20.94 million$31.30 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/18/2016Q415($0.50)($1.08)$28.78 million$6.22 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2015Q315($0.89)($1.07)$17.21 million$5.80 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2015Q215($0.46)($0.85)$25.75 million$13.20 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/7/2015Q115($0.92)($0.13)$10.86 million$34.20 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/17/2015Q414($0.58)($0.76)$10.94 million$14.64 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/7/2014Q314($0.53)$0.10$8.45 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/7/2014Q2($0.41)($0.54)$11.00 million$8.41 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/8/2014Q1($0.38)($0.39)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/6/2014Q4($0.34)($0.40)$6.19 million$6.70 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/7/2013($0.28)($0.47)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Agios Pharmaceuticals (NASDAQ:AGIO)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20162($0.56)($0.48)($0.52)
Q2 20163($1.33)($1.15)($1.23)
Q3 20163($1.42)($1.19)($1.30)
Q4 20163($1.49)($0.91)($1.23)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Agios Pharmaceuticals (NASDAQ:AGIO)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Agios Pharmaceuticals (NASDAQ:AGIO)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
7/26/2016Lewis Clayton Jr. CantleyDirectorSell2,504$42.80$107,171.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/25/2016Lewis Clayton Jr. CantleyDirectorSell627$41.85$26,239.95View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/28/2016Lewis Clayton Jr. CantleyDirectorSell2,504$41.88$104,867.52View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/27/2016Lewis Clayton Jr. CantleyDirectorSell627$40.37$25,311.99View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/8/2016Scott BillerInsiderSell27,500$65.00$1,787,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/26/2016Lewis Clayton Jr. CantleyDirectorSell2,504$51.69$129,431.76View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/26/2016Lewis Clayton Jr. CantleyDirectorSell2,504$53.44$133,813.76View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/25/2016Lewis Clayton Jr. CantleyDirectorSell627$55.00$34,485.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/30/2016Lewis Clayton Jr. CantleyDirectorSell2,504$37.19$93,123.76View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/26/2016Lewis Clayton Jr. CantleyDirectorSell2,504$37.90$94,901.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/29/2016Lewis Clayton Jr. CantleyDirectorSell2,504$42.93$107,496.72View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/29/2015Lewis Clayton Jr. CantleyDirectorSell10,664$64.93$692,413.52View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/15/2015John Duncan HiggonsCOOSell20,000$50.09$1,001,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/17/2015Lewis Clayton Jr. CantleyDirectorSell9,408$59.83$562,880.64View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/16/2015John Duncan HiggonsCOOSell20,000$61.51$1,230,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/2/2015Scott BillerinsiderSell5,500$77.12$424,160.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/23/2015Lewis Clayton Jr. CantleyDirectorSell9,704$61.16$593,496.64View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/15/2015John Duncan HiggonsCOOSell20,000$71.04$1,420,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/30/2015Scott BillerinsiderSell5,500$70.44$387,420.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/25/2015Lewis Clayton Jr. CantleyDirectorSell9,704$83.25$807,858.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/24/2015Glenn GoddardSVPSell6,000$85.97$515,820.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/15/2015John Duncan HiggonsCOOSell20,000$91.11$1,822,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/18/2015Lewis Clayton Jr. CantleyDirectorSell9,704$94.94$921,297.76View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/17/2015John Duncan HiggonsCOOSell20,000$92.24$1,844,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/23/2015Glenn GoddardSVPSell7,000$120.45$843,150.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/20/2015Scott BillerInsiderSell5,500$113.87$626,285.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/17/2015Glenn GoddardSVPSell13,000$113.71$1,478,230.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/16/2015John Duncan HiggonsCOOSell20,000$114.02$2,280,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/16/2015Lewis Clayton Jr. CantleyDirectorSell9,704$114.28$1,108,973.12View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/25/2015Lewis Clayton Jr. CantleyDirectorSell9,704$105.13$1,020,181.52View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/15/2015John Duncan HiggonsCOOSell7,000$105.23$736,610.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/8/2015Scott BillerInsiderSell5,500$121.85$670,175.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/1/2015Christopher BowdenInsiderSell5,000$120.67$603,350.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/1/2015David P SchenkeinCEOSell13,000$120.67$1,568,710.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/27/2015David P SchenkeinCEOSell8,929$120.05$1,071,926.45View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/27/2015Glenn GoddardSVPSell2,171$120.05$260,628.55View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/20/2015Lewis Clayton Jr. CantleyDirectorSell9,704$116.64$1,131,874.56View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/15/2015John Duncan HiggonsCOOSell7,417$112.89$837,305.13View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/12/2015David P SchenkeinCEOSell5,200$110.02$572,104.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/8/2015David P SchenkeinCEOSell3,900$101.32$395,148.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/7/2015Scott BillerInsiderSell5,500$96.32$529,760.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/24/2015Lewis Clayton Jr. CantleyDirectorSell9,704$105.15$1,020,375.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/15/2015John Duncan HiggonsCOOSell6,583$99.54$655,271.82View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/13/2015David P SchenkeinCEOSell3,900$100.03$390,117.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/8/2015Scott BillerInsiderSell5,500$97.64$537,020.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/1/2015David P SchenkeinCEOSell3,900$92.54$360,906.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/27/2015Lewis Clayton Jr. CantleyDirectorSell9,704$93.58$908,100.32View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/16/2015Glenn GoddardSVPSell10,000$106.24$1,062,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/16/2015John Duncan HiggonsCOOSell7,000$106.24$743,680.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/16/2015Scott BillerInsiderSell5,500$106.81$587,455.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/2/2015David P SchenkeinCEOSell7,800$107.05$834,990.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/13/2015David P SchenkeinCEOSell1,471$120.22$176,843.62View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/13/2015Glenn GoddardSVPSell1,316$120.31$158,327.96View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/11/2015Glenn GoddardSVPSell16,513$107.12$1,768,872.56View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/9/2015Glenn GoddardSVPSell15,000$105.81$1,587,150.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/2/2015David P SchenkeinCEOSell10,400$114.31$1,188,824.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/2/2015David P SchenkeinCEOSell13,000$110.08$1,431,040.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/2/2015John Duncan HiggonsCOOSell12,000$110.08$1,320,960.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/2/2015Scott BillerInsiderSell4,500$110.08$495,360.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/16/2014Celgene European Investment CoMajor ShareholderBuy228,645$110.75$25,322,433.75View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/16/2014John MaraganoreDirectorBuy1,806$110.75$200,014.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/1/2014David P SchenkeinCEOSell13,000$97.03$1,261,390.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/1/2014John Duncan HiggonsCOOSell12,000$97.03$1,164,360.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/1/2014Scott BillerInsiderSell4,500$97.03$436,635.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/3/2014Glenn GoddardSVPSell2,000$81.71$163,420.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/3/2014John Duncan HiggonsCOOSell13,000$81.71$1,062,230.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/3/2014Scott BillerInsiderSell4,500$81.71$367,695.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/1/2014Glenn GoddardSVPSell1,500$60.07$90,105.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/1/2014John Duncan HiggonsCOOSell13,000$60.07$780,910.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/1/2014Scott BillerInsiderSell4,500$60.07$270,315.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/26/2014David P SchenkeinCEOSell60,000$62.68$3,760,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/26/2014Glenn GoddardSVPSell17,500$56.53$989,275.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/19/2014Scott BillerInsiderSell37,996$50.45$1,916,898.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/2/2014Glenn GoddardSVPSell10,000$46.30$463,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/2/2014John Duncan HiggonsCOOSell13,000$46.30$601,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/2/2014Scott BillerInsiderSell4,500$46.30$208,350.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/26/2014John Duncan HiggonsCOOSell5,000$45.05$225,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/11/2014David P SchenkeinCEOSell4,530$40.17$181,970.10View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2014David P SchenkeinCEOSell13,000$46.52$604,760.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2014Glenn GoddardSVPSell3,500$46.52$162,820.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2014John Duncan HiggonsCOOSell12,000$46.52$558,240.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2014Scott BillerInsiderSell4,500$46.52$209,340.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/23/2014John MaraganoreDirectorBuy2,300$43.98$101,154.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/20/2014Scott BillerInsiderSell2,004$50.05$100,300.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/13/2014John Duncan HiggonsCOOSell5,000$45.27$226,350.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/3/2014John Duncan HiggonsCOOSell7,000$34.47$241,290.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/6/2014John Duncan HiggonsCOOSell5,000$45.73$228,650.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/1/2014Glenn GoddardSVPSell2,000$42.39$84,780.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/1/2014John Duncan HiggonsCOOSell7,000$42.39$296,730.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/1/2014Scott BillerInsiderSell4,500$42.39$190,755.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/29/2014Celgene European Investment Comajor shareholderBuy294,800$44.00$12,971,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/29/2014John MaraganoreDirectorBuy2,250$44.00$99,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/7/2014Glenn GoddardSVPSell2,000$45.17$90,340.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/7/2014John Duncan HiggonsCOOSell3,000$45.17$135,510.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/1/2014Glenn GoddardSVPSell4,000$38.08$152,320.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/1/2014John Duncan HiggonsCOOSell12,000$38.08$456,960.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/1/2014Scott BillerInsiderSell4,500$38.08$171,360.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/7/2014Glenn GoddardSVPSell17,468$42.11$735,577.48View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/7/2014John Duncan HiggonsCOOSell14,646$41.41$606,490.86View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/3/2014John Duncan HiggonsCOOSell8,000$29.85$238,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/3/2014Scott BillerInsiderSell6,000$29.85$179,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/10/2014Glenn GoddardSVPSell6,000$30.44$182,640.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/27/2014Glenn GoddardSVPSell7,000$26.29$184,030.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/21/2014Glenn GoddardSVPSell10,000$34.71$347,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/29/2013Celgene European Investment CoMajor ShareholderBuy708,333$18.00$12,749,994.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Agios Pharmaceuticals (NASDAQ:AGIO)
DateHeadline
07/28/16 03:01 PMAgios to Webcast Conference Call of Second Quarter 2016 Financial Results on August 4, 2016 - [GlobeNewswire] - CAMBRIDGE, Mass., July 28, 2016-- Agios Pharmaceuticals, Inc., a leader in the fields of cancer metabolism and rare genetic metabolic disorders, today announced that the company will host a conference ...
07/26/16 11:31 AMCan Shares Of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Hit $90? - Investor Newswire
07/25/16 02:33 PMNew Broker Ratings For Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - FTSE News
07/23/16 02:21 PMStock Up Nicely This Week: Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - TGP
07/22/16 02:21 PMEarnings Focus and Crowd Sourced Sentiment Review for Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - TGP
07/22/16 02:21 PMAgios Pharmaceuticals, Inc. (NASDAQ:AGIO) Rose 1.03%: Verizon Communications Inc. (NYSE:VZ), Canadian Solar ... - KC Register
07/21/16 02:21 PMBroker Outlook For Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - Fiscal Standard
07/20/16 09:35 PMBig Pharma’s cash flows in a flurry of partnerships
07/20/16 03:10 PMStock Moving Lower for the Month; Investor Update on Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - Engelwood Daily
07/20/16 03:10 PMHow Many Agios Pharmaceuticals Inc (NASDAQ:AGIO)'s Analysts Are Bullish? - Press Telegraph
07/19/16 02:22 PMAgios Pharmaceuticals, Inc. (NASDAQ:AGIO) Updated Price Targets - FTSE News
07/19/16 02:22 PMEquity Roundup: Stock Performance Focus on Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - Press Telegraph
07/19/16 12:11 PMAgios Pharmaceuticals draws bullish bet -
07/19/16 06:20 AM​Cambridge’s Jounce announces hefty $2.5B deal with Celgene for cancer drugs -
07/19/16 06:01 AMCelgene, Jounce Therapeutics in Early Cancer Immunotherapy Development Pact -
07/18/16 02:23 PMAgios Pharmaceuticals, Inc. (NASDAQ:AGIO) Earnings Concentration and Analyst Target Watch - Engelwood Daily
07/18/16 02:23 PMShares of Agios Pharmaceuticals (AGIO) Drops by -2.36% - Trade Calls
07/18/16 02:23 PMIs $90 Price Target Attainable For Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)? - Investor Newswire
07/16/16 10:46 AMShares Experiencing a Downtrend: Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - TGP
07/16/16 10:46 AMAgios Pharmaceuticals Inc. (AGIO) Drops 7.13% on July 13 - Equities.com
07/15/16 12:56 PMMarket research outlook on global leukemia therapeutic, 2014-2020 just published
07/14/16 02:22 PMEye on Stock Volatility for: Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - Engelwood Daily
07/14/16 02:22 PMIs Selling Agios Pharmaceuticals Inc Here a Winning Strategy? - Consumer Eagle
07/14/16 02:22 PMFirst Week of July 15th Options Trading For Agios Pharmaceuticals (AGIO) - Nasdaq
07/14/16 02:22 PMAgios Pharmaceuticals Inc versus Retrophin Inc Head to Head Compare - CML News
07/14/16 11:12 AMFirst Week of July 15th Options Trading For Agios Pharmaceuticals (AGIO)
07/12/16 07:50 PMShares Losing Ground for the Month; Investor Alert on Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - Engelwood Daily
07/12/16 02:23 PMTrading Performance and Target Watch for Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - Press Telegraph
07/12/16 07:52 AMEvelo Biosciences and Epiva Biosciences Merge to Create the Leading Immuno-Microbiome Platform Company
07/11/16 07:25 PMStrong Sell Calls For Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) At 0 - Investor Newswire
07/11/16 02:22 PMAgios Pharmaceuticals Inc Stock Momentum at Critical Inflection Point - CML News
07/11/16 07:09 AMCompany Stock Focus for Agios Pharmaceuticals, Inc. (NASDAQ:AGIO): Which Way Will Shares Head? - Press Telegraph
07/10/16 07:09 AMPuma Biotechnology : What Investors are Making of These Biotech Stocks? - Grifols, Achillion Pharma, Agios Pharma, and Puma Biotech
07/09/16 10:28 AMAgios Pharmaceuticals Incorporated (NASDAQ:AGIO) Sellers Increased By 13.08% Their Shorts - Engelwood Daily
07/08/16 10:24 AMWall Street Ratings and Target Price Views on Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - Telanagana Press
07/08/16 10:24 AMWhat Investors are Making of These Biotech Stocks? - Grifols, Achillion Pharma, Agios Pharma, and Puma Biotech - PR Newswire (press release)
07/07/16 02:22 PMInsiders are Gradually Selling Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - Telanagana Press
07/07/16 02:22 PMAgios Pharmaceuticals, Inc. (NASDAQ:AGIO) Stock Update: Check on Ratings and Target Price - Telanagana Press
07/07/16 02:22 PMAgios Pharmaceuticals, Inc. versus Intrexon Corporation Head to Head Compare - CML News
07/06/16 02:22 PMAgios Pharmaceuticals, Inc. (NASDAQ:AGIO) Current Analyst Ratings - Fiscal Standard
07/06/16 07:09 AMCan Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Improve on the Earnings Front? - Engelwood Daily
07/06/16 07:09 AMStock Rating Watch and Earnings Insight for Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - Press Telegraph
07/04/16 02:21 PMAgios Pharmaceuticals, Inc. (NASDAQ:AGIO) Expected to Reach Highs Of $90 - Investor Newswire
07/04/16 07:09 AM3 Big Reasons Agios Pharmaceuticals, Inc. Has Plunged 38% in 2016 - Motley Fool
07/03/16 03:05 PM3 Big Reasons Agios Pharmaceuticals, Inc. Has Plunged 38% in 2016 -
07/03/16 07:09 AMCan Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Surprise Analysts this Quarter? - Investor Newswire
07/01/16 07:36 PMTracking Stock Volatility for: Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - Engelwood Daily
06/30/16 10:15 AMRecent Study: Gallbladder Cancer - Pipeline Review, H1 2016
06/29/16 10:36 AMRecently Issued Stock Ratings For Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - Fiscal Standard
06/28/16 07:34 AMTop Stock Pick for Quarter: Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - Engelwood Daily

Social

About Agios Pharmaceuticals

Agios Pharmaceuticals logoAgios Pharmaceuticals, Inc. (Agios) is a biopharmaceutical company. The Company is engaged in the discovery and development of orally available small molecule medicines for the treatment of cancer and rare genetic disorders (RGDs) of metabolism using cellular metabolism as a platform. It is also engaged in the identification and validation of altered metabolic pathways within abnormal cells. Its products include AG-221, AG-120 and AG-348. Its lead product AG-348 in the RGD program is an orally available small molecule that targets pyruvate kinase-R for the treatment of pyruvate kinase deficiency. AG-221 is potent inhibitor of the mutated IDH2 protein being developed for the treatment hematological malignancies and advanced solid tumors. AG-120 is an orally available, selective, potent inhibitor of the mutated IDH1 protein being developed for the treatment hematological malignancies and advanced solid tumors.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: AGIO
  • CUSIP:
Key Metrics:
  • Previous Close: $43.86
  • 50 Day Moving Average: $44.82
  • 200 Day Moving Average: $45.23
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $1.66B
  • Beta: 1.98
  • Current Year EPS Consensus Estimate: $-3.46 EPS
  • Next Year EPS Consensus Estimate: $-4.93 EPS
Additional Links:
Agios Pharmaceuticals (NASDAQ:AGIO) Chart for Friday, July, 29, 2016